Emergent BioSolutions says HHS to continue buying Anthrax vaccine
http://www.abcmoney.co.uk/news/192007167797.htm
Comment:
HHS continues to throw money down the rabbit hole, and continues to put the public at risk with the anthrax vaccine.
http://www.abcmoney.co.uk/news/192007167797.htm
NEW YORK (Thomson Financial) - Emergent BioSolutions Inc. Monday said the Department of Health and Human Services plans to continue purchasing BioThrax, an anthrax vaccine, under the current contract for 18.75 million doses for a fixed price of $400 million.
The contract includes an additional $34 million upon receipt of regulatory approval of four-year dating.
'The HHS contract provides us with a baseline of revenue sufficient to support the growth and profitability of our company in 2008 and 2009, and we intend to expand our revenue sources, including with the Department of Defense,' the Rockville, Md.-based company said.
Shares of the immunobiotics-focused biopharmaceutical company were up by 3 cents at $5.10.
Melinda Peer
Comment:
HHS continues to throw money down the rabbit hole, and continues to put the public at risk with the anthrax vaccine.
http://www.abcmoney.co.uk/news/192007167797.htm
NEW YORK (Thomson Financial) - Emergent BioSolutions Inc. Monday said the Department of Health and Human Services plans to continue purchasing BioThrax, an anthrax vaccine, under the current contract for 18.75 million doses for a fixed price of $400 million.
The contract includes an additional $34 million upon receipt of regulatory approval of four-year dating.
'The HHS contract provides us with a baseline of revenue sufficient to support the growth and profitability of our company in 2008 and 2009, and we intend to expand our revenue sources, including with the Department of Defense,' the Rockville, Md.-based company said.
Shares of the immunobiotics-focused biopharmaceutical company were up by 3 cents at $5.10.
Melinda Peer
